BidaskClub cut shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a buy rating to a hold rating in a research report report published on Tuesday morning.

Other equities research analysts also recently issued research reports about the stock. Laidlaw initiated coverage on shares of Marinus Pharmaceuticals in a research note on Thursday, December 14th. They set a buy rating and a $18.00 price target on the stock. JMP Securities reaffirmed an outperform rating and set a $11.00 price target (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 12th. Finally, ValuEngine downgraded shares of Marinus Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, December 1st.

Marinus Pharmaceuticals (NASDAQ MRNS) traded down $0.23 during trading hours on Tuesday, hitting $7.34. 615,572 shares of the company traded hands, compared to its average volume of 1,730,000. The firm has a market cap of $296.76, a price-to-earnings ratio of -7.89 and a beta of 2.44. Marinus Pharmaceuticals has a 1-year low of $1.06 and a 1-year high of $9.87.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.02.

In related news, major shareholder Bain Capital Life Sciences Inv sold 822,547 shares of Marinus Pharmaceuticals stock in a transaction on Friday, December 15th. The shares were sold at an average price of $8.10, for a total transaction of $6,662,630.70. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 6.40% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter worth about $128,000. Citadel Advisors LLC increased its position in shares of Marinus Pharmaceuticals by 327.8% in the 3rd quarter. Citadel Advisors LLC now owns 51,383 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 39,371 shares during the last quarter. Susquehanna International Group LLP bought a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter worth about $503,000. EAM Investors LLC bought a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter worth about $554,000. Finally, Iguana Healthcare Management LLC bought a new stake in shares of Marinus Pharmaceuticals in the 3rd quarter worth about $1,027,000. 49.77% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Marinus Pharmaceuticals (MRNS) Rating Lowered to Hold at BidaskClub” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.watchlistnews.com/marinus-pharmaceuticals-mrns-rating-lowered-to-hold-at-bidaskclub/1806161.html.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.